SGLT2 inhibitors: forging a better future for people living with CKD

Boehringer Ingelheim and Eli Lilly and Company |

Chair: Merlin Thomas (AUS)

18:45 – 18:50Welcome and introductions: faculty and the patient storyMerlin Thomas (AUS)
18:50 – 19:00Perspectives for managing patients with CKD: what can we do today?Janaka Karalliedde (UK)
19:00 – 19:15Protecting the kidneys now by slowing kidney function decline: empagliflozin and other SGLT2 inhibitors in actionPaola Fioretto (ITA)
19:15 – 19:25Championing a better future for those living with CKD: act now to preserve kidney functionSarah Davies (UK)
19:25 – 19:42Audience/panel Q&AMerlin Thomas (AUS)
19:42 – 19:45Summary and closeMerlin Thomas (AUS)